MAIT Cell Inhibition for Treatment-Resistant Rheumatoid Arthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis, such as methotrexate and biologics, fail to respond in approximately 30% of patients, and the response varies significantly among individuals due to differing pathophysiological mechanisms, necessitating new therapeutic targets.
Innovation Solution
Inhibiting the activation of Mucosal-Associated Invariant T (MAIT) cells using agents like small organic molecules or antibodies to treat rheumatoid arthritis, particularly in patients resistant to conventional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (methotrexate and biologics) are used to treat rheumatoid arthritis, then joint inflammation and pain are reduced in most patients, but approximately 30% of patients show no response due to varying pathophysiological mechanisms
Solution Approach 1:
The patent segments the RA patient population into different subgroups based on their pathophysiological mechanisms and identifies MAIT cell-mediated inflammation as a distinct therapeutic target. By focusing on this specific subset of patients with MAIT cell-driven inflammation, the treatment achieves reliable responses in previously non-responsive populations, resolving the contradiction between overall response rate and applicability to diverse patient subgroups.
2Adaptability or versatility
If multiple different biologic agents targeting various immune pathways are used, then treatment options increase for different patient types, but treatment complexity and difficulty in selecting the appropriate agent increase
Solution Approach 1:
The patent employs biomarker-based feedback mechanisms to guide treatment selection. By measuring MAIT cell activation status and related biomarkers, clinicians can objectively determine which patients will respond to MAIT cell-targeted therapies, simplifying the decision-making process among multiple biologic options and reducing treatment selection complexity.
3Reliability
If current immunotherapies are used to suppress inflammation, then joint damage is limited in responding patients, but no new therapeutic targets have been identified for the 30% of patients who do not respond
Solution Approach 1:
The patent extracts and isolates the MAIT cell pathway as a distinct therapeutic target from the complex web of immune mechanisms in RA. By specifically targeting MR1-restricted MAIT cells and their activation pathways, the invention provides a new therapeutic avenue for patients who do not respond to conventional immunotherapies, thereby expanding the availability of treatment options without compromising joint protection in existing therapies.
Data Source
AI summary
Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis